SCHEMBL30633740

SCHEMBL30633740

COC(=O)c1cc(=O)c2c(Cl)cc(Br)cc2n1C(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2C19 P33261 2/20 0.40
ALDH1A1 P00352 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
MAPT P10636 3/20 0.33
THRB P10828 2/20 0.33
TP53 P04637 2/20 0.33
ACLY P53396 2/20 0.32
PKM P14618 1/20 0.32
MEN1 O00255 1/20 0.32
TSHR P16473 1/20 0.32
KMT2A Q03164 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
MAPK10 P53779 2/20 0.31
USP2 O75604 1/20 0.31
MAPK1 P28482 1/20 0.31
PTGS2 P35354 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26613897 1.00 KDM4E (0.40) KDM4ECYP1A2CYP2C19ALDH1A1CYP3A4
SCHEMBL30633783 0.86 MCL1 (0.35) CYP1A2CYP2C19ALDH1A1CYP2C9MAPT
SCHEMBL26613922 0.86 MCL1 (0.35) CYP1A2CYP2C19ALDH1A1CYP2C9MAPT
SCHEMBL30633686 0.85 ALDH1A1 (0.46) KDM4ECYP1A2CYP2C19ALDH1A1CYP3A4
SCHEMBL26613856 0.85 WDR5 (0.32) MAPK1
SCHEMBL26613912 0.85 ALDH1A1 (0.46) KDM4ECYP1A2CYP2C19ALDH1A1CYP3A4
SCHEMBL30633716 0.85 WDR5 (0.32) MAPK1
SCHEMBL23049627 0.69 KDM4E (0.48) KDM4EKMT2AL3MBTL1
SCHEMBL20604833 0.69 ALDH1A1 (0.46) KDM4ECYP1A2CYP2C19ALDH1A1CYP3A4
SCHEMBL7881984 0.67 ALDH1A1 (0.50) KDM4ECYP1A2CYP2C19ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136586-A1 Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors BEIGENE, LTD. (KY) 2025-05-01 US disclosed
EP-4514797-A1 SUBSTITUTED 7- (PYRIMIDIN-4-YL) QUINOLIN-4 (1H) -ONE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS BeiGene, Ltd. (KY) 2025-03-05 EP disclosed
CN-119053598-A Substituted 7- (pyrimidin-4-yl) quinolin-4 (1H) -one compounds as cyclin dependent kinase inhibitors 百济神州有限公司 2024-11-29 CN disclosed
WO-2023208172-A1 SUBSTITUTED 7- (PYRIMIDIN-4-YL) QUINOLIN-4 (1H) -ONE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS BEIGENE , LTD. (KY) 2023-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136586-A1 Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors CDK4, CDK7, CDK8 KDM4E 527/4885CYP1A2 3256/4885CYP2C19 2955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.